Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
December 14, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … TheraPanacea; the potential of our commercial business and pipeline programs; and our strategy and plans. These … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
Biogen Reports Quarterly Revenues of $3.1 Billion
April 24, 2018 - … enhanced our collaboration with Ionis to develop a new pipeline of gene-based therapies for neurological diseases.” … and plans; potential of our commercial business and pipeline programs; capital allocation and investment … enhanced our collaboration with Ionis to develop a new pipeline of gene-based therapies for neurological diseases.” …
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
December 8, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … of MDD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
December 1, 2021 - … of MDD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … of MDD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … of MDD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated …
Update on Regulatory Review of Aducanumab in the European Union
November 17, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … of, and expectations for, Biogen’s commercial business and pipeline programs, including ADUHELM; planning and timing for … Eisai; the potential of Biogen’s commercial business and pipeline programs, including ADUHELM; and risks and …
The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis
November 16, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
November 15, 2021 - … neuroscience R&D team in the industry and a leading pipeline with approximately 30 clinical programs, including … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and plans and the potential of our commercial business and pipeline programs; capital allocation and investment …
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
November 15, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
November 11, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 11, 2021 - … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of …
